ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2009

Feb 3, 2009

SEC Form 4/A — Form 4/A

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2008-08-21

Reporting Person: Cormack Scott Daniel (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2008-08-21	stock option (right to buy)	$3.889	A	24825	Acquired	2009-01-01	Common Stock (24825)	Direct
2008-08-21	Stock option (right to buy)	$3.889	A	871	Acquired	2009-08-01	Common stock (871)	Indirect
2008-08-21	Stock option (right to buy)	$3.889	A	7077	Acquired	2010-02-01	Common Stock (7077)	Indirect
2008-08-21	Stock option (right to buy)	$3.889	A	20470	Acquired	2010-12-16	Common Stock (20470)	Direct
2008-08-21	Stock option (right to buy)	$3.889	A	6533	Acquired	2010-12-16	Common stock (6533)	Indirect
2008-08-21	Stock option (right to buy)	$3.889	A	21559	Acquired	2011-01-14	Common Stock (21559)	Direct
2008-08-21	Stock option (right to buy)	$3.889	A	6859	Acquired	2011-01-14	Common Stock (6859)	Indirect
2008-08-21	Stock option (right to buy)	$4.1051	A	46167	Acquired	2012-08-08	Common Stock (46167)	Direct

Footnotes

F1: Due to an administrative error, the original Form 4 overstated the exercise price by $0.0025.

F2: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 16.

F3: Received in exchange for a stock option to acquire 114,000 shares of OncoGenex Technologies Inc. ("OncoGenex Technologies") common stock for CAD$0.90 per share in connection with an arrangement between OncoGenex Technologies and OncoGenex Pharmaceuticals, Inc. (the "Arrangement").

F4: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 1.

F5: Received in the Arrangement in exchange for a stock option to acquire 4,000 shares of OncoGenex Technologies common stock for CAD$0.90 per share.

F6: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 4.

F7: Received in the Arrangement in exchange for a stock option to acquire 32,500 shares of OncoGenex Technologies common stock for CAD$0.90 per share.

F8: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 13.

F9: Received in the Arrangement in exchange for a stock option to acquire 94,000 shares of OncoGenex Technologies common stock for CAD$0.90 per share.

F10: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 5.

F11: Received in the Arrangement in exchange for a stock option to acquire 30,000 shares of OncoGenex Technologies common stock for CAD$0.90 per share.

F12: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 14.

F13: Received in the Arrangement in exchange for a stock option to acquire 99,000 shares of OncoGenex Technologies common stock for CAD$0.90 per share.

F14: Received in the Arrangement in exchange for a stock option to acquire 31,500 shares of OncoGenex Technologies common stock for CAD$0.90 per share.

F15: Due to an administrative error, the original Form 4 overstated the exercise price by $0.0026.

F16: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 30.

F17: Received in the Arrangement in exchange for a stock option to acquire 212,000 shares of OncoGenex Technologies common stock for CAD$0.95 per share.